NASDAQ:DCTH Delcath Systems - DCTH Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Delcath Systems, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $3.75 +0.02 (+0.54%) (As of 01/27/2023 12:00 AM ET) Add Compare Share Share Today's Range$3.71▼$3.7850-Day Range$2.77▼$3.9252-Week Range$2.34▼$7.75Volume7,352 shsAverage Volume16,825 shsMarket Capitalization$37.69 millionP/E RatioN/ADividend YieldN/APrice Target$17.33 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Delcath Systems MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside362.2% Upside$17.33 Price TargetShort InterestBearish1.75% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.55Based on 3 Articles This WeekInsider TradingAcquiring Shares$55,078 Bought Last QuarterProj. Earnings GrowthGrowingFrom ($3.77) to ($1.64) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.02 out of 5 starsMedical Sector642nd out of 1,054 stocksSurgical & Medical Instruments Industry66th out of 105 stocks 3.5 Analyst's Opinion Consensus RatingDelcath Systems has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $17.33, Delcath Systems has a forecasted upside of 362.2% from its current price of $3.75.Amount of Analyst CoverageDelcath Systems has received no research coverage in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted1.75% of the outstanding shares of Delcath Systems have been sold short.Short Interest Ratio / Days to CoverDelcath Systems has a short interest ratio ("days to cover") of 7.5.Change versus previous monthShort interest in Delcath Systems has recently increased by 0.46%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldDelcath Systems does not currently pay a dividend.Dividend GrowthDelcath Systems does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for DCTH. Previous Next 2.0 News and Social Media Coverage News SentimentDelcath Systems has a news sentiment score of 0.55. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.72 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Delcath Systems this week, compared to 0 articles on an average week. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Delcath Systems insiders have bought more of their company's stock than they have sold. Specifically, they have bought $55,078.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders16.76% of the stock of Delcath Systems is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 25.66% of the stock of Delcath Systems is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Delcath Systems are expected to grow in the coming year, from ($3.77) to ($1.64) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Delcath Systems is -0.99, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Delcath Systems is -0.99, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioDelcath Systems has a P/B Ratio of 2.31. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Delcath Systems (NASDAQ:DCTH) StockDelcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan hydrochloride for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with hepatic dominant ocular melanoma to investigate objective response rate in metastatic ocular melanoma. The company also provides HEPZATO as a stand-alone medical device for sale under the CHEMOSAT Hepatic Delivery System for Melphalan trade name for medical centers to treat a range of liver cancers in Europe. Delcath Systems, Inc. was incorporated in 1988 and is headquartered in New York, New York.Read More Receive DCTH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Delcath Systems and its competitors with MarketBeat's FREE daily newsletter. Email Address DCTH Stock News HeadlinesJanuary 25, 2023 | americanbankingnews.comDelcath Systems (NASDAQ:DCTH) Now Covered by Analysts at StockNews.comJanuary 24, 2023 | americanbankingnews.comDelcath Systems, Inc. (NASDAQ:DCTH) Sees Significant Drop in Short InterestJanuary 29, 2023 | Porter & Company (Ad)The Next Big Crisis Is HereYou just can’t see it yet because it’s NOT a banking, financial, or economic crisis… it’s far worse and threatens every dollar in your retirement account.January 17, 2023 | finance.yahoo.comDelcath Systems Announces Updated Results from CHOPIN Phase 1b Trial Published in Cardiovascular and Interventional RadiologyDecember 16, 2022 | finance.yahoo.comDelcath Systems Announces Inducement of Grant Under NASDAQ Listing Rule 5635(C)(4)December 13, 2022 | finance.yahoo.comDelcath Systems Closes Private Placement of $6.2 MillionDecember 8, 2022 | marketwatch.comDelcath Shares Climb on $6.2 Million Private PlacementDecember 8, 2022 | finance.yahoo.comDelcath Systems Announces Private Placement of $6.2 MillionJanuary 29, 2023 | Porter & Company (Ad)The Next Big Crisis Is HereYou just can’t see it yet because it’s NOT a banking, financial, or economic crisis… it’s far worse and threatens every dollar in your retirement account.December 6, 2022 | msn.comDelcath Systems's Return On Capital Employed OverviewDecember 5, 2022 | finance.yahoo.comResults of a Single Center Study on Delcath's CHEMOSAT® Hepatic Delivery System In the Treatment of Cholangiocarcinoma Published in the Journal Clinical & Experimental MetastasisNovember 9, 2022 | finance.yahoo.comDelcath Systems Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)November 8, 2022 | nasdaq.comDelcath Systems, Inc. (DCTH) Reports Q3 Loss, Tops Revenue EstimatesNovember 8, 2022 | nasdaq.comDelcath Systems Inc. Q3 Loss beats estimatesNovember 8, 2022 | finance.yahoo.comDelcath Systems Reports Third Quarter 2022 Results and Provides Business UpdateOctober 24, 2022 | finance.yahoo.comDelcath Systems to Host Third Quarter 2022 ResultsSeptember 1, 2022 | finance.yahoo.comDelcath Systems to Participate at the H.C. Wainwright 24th Annual Global Investor Conference on September 12 and 13, 2022August 19, 2022 | seekingalpha.comDelcath Systems (DCTH) Investor Presentation - SlideshowAugust 8, 2022 | nasdaq.comDelcath Systems, Inc. (DCTH) Reports Q2 Loss, Lags Revenue EstimatesAugust 8, 2022 | seekingalpha.comDelcath Systems, Inc. (DCTH) CEO Gerard Michel on Q2 2022 Results - Earnings Call TranscriptAugust 8, 2022 | finance.yahoo.comDelcath Systems Reports Second Quarter 2022 Results and Provides Business UpdateAugust 5, 2022 | msn.comEarnings Outlook For Delcath SystemsAugust 5, 2022 | finance.yahoo.comResults of a Multicenter Study on Delcath's CHEMOSAT® Hepatic Delivery System Published in Cardiovascular and Interventional RadiologyJuly 27, 2022 | finance.yahoo.comDelcath Systems to Present at Upcoming Investor Conferences in AugustJuly 21, 2022 | nasdaq.comThursday 7/21 Insider Buying Report: KDP, DCTHJuly 20, 2022 | finance.yahoo.comDelcath Systems Closes Private Placement of $5.0 MillionJuly 18, 2022 | finance.yahoo.comDelcath Systems Announces Private Placement of $5.0 MillionSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive DCTH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Delcath Systems and its competitors with MarketBeat's FREE daily newsletter. Email Address DCTH Company Calendar Last Earnings11/08/2022Today1/29/2023Next Earnings (Estimated)3/24/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Surgical & medical instruments Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:DCTH CUSIPN/A CIK872912 Webdelcath.com Phone212-489-2100Fax212-489-2102Employees55Year FoundedN/APrice Target and Rating Average Stock Price Forecast$17.33 High Stock Price Forecast$19.00 Low Stock Price Forecast$14.00 Forecasted Upside/Downside+362.2%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($3.79) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-25,650,000.00 Net Margins-757.05% Pretax MarginN/A Return on Equity-1,396.28% Return on Assets-124.69% Debt Debt-to-Equity RatioN/A Current Ratio1.28 Quick Ratio1.15 Sales & Book Value Annual Sales$3.56 million Price / Sales10.59 Cash FlowN/A Price / Cash FlowN/A Book Value$1.62 per share Price / Book2.31Miscellaneous Outstanding Shares10,050,000Free Float8,363,000Market Cap$37.69 million OptionableNot Optionable Beta0.87 Key ExecutivesMr. Gerard J. Michel MBA (Age 60)MS, CEO & Director Comp: $683.82kMr. John Purpura M.S. (Age 62)Chief Operating Officer Comp: $482.56kDr. Johnny John M.D. (Age 59)Sr. VP Clinical Devel. & Medical Affairs Comp: $383.63kMr. Anthony C. Dias (Age 56)VP of Fin. Mr. David HoffmanGen. Counsel, Corp. Sec. & Chief Compliance OfficerMr. Robin WaggeSr. VP of Rubenstein AssociatesMr. Kevin MuirVP of Commercial OperationsMore ExecutivesKey CompetitorsVapothermNYSE:VAPOIsorayNYSE:ISRPAVmedNASDAQ:PAVMBrainsWayNASDAQ:BWAYVivos TherapeuticsNASDAQ:VVOSView All CompetitorsInsiders & InstitutionsRosalind Advisors, Inc.Bought 15,215 shares on 12/14/2022Total: $55,078.30 ($3.62/share)Gerard J MichelBought 62,814 shares on 7/20/2022Total: $249,999.72 ($3.98/share)John PurpuraBought 3,300 shares on 5/16/2022Total: $15,213.00 ($4.61/share)Steven A J SalamonBought 6,000 shares on 5/12/2022Total: $29,400.00 ($4.90/share)Steven A J SalamonBought 1,600 shares on 4/19/2022Total: $10,000.00 ($6.25/share)View All Insider Transactions DCTH Stock - Frequently Asked Questions Should I buy or sell Delcath Systems stock right now? 3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Delcath Systems in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" DCTH shares. View DCTH analyst ratings or view top-rated stocks. What is Delcath Systems' stock price forecast for 2023? 3 brokerages have issued 1-year price targets for Delcath Systems' stock. Their DCTH share price forecasts range from $14.00 to $19.00. On average, they expect the company's share price to reach $17.33 in the next year. This suggests a possible upside of 362.2% from the stock's current price. View analysts price targets for DCTH or view top-rated stocks among Wall Street analysts. How have DCTH shares performed in 2023? Delcath Systems' stock was trading at $3.60 on January 1st, 2023. Since then, DCTH shares have increased by 4.2% and is now trading at $3.75. View the best growth stocks for 2023 here. When is Delcath Systems' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Friday, March 24th 2023. View our DCTH earnings forecast. How were Delcath Systems' earnings last quarter? Delcath Systems, Inc. (NASDAQ:DCTH) announced its quarterly earnings results on Tuesday, November, 8th. The company reported ($0.92) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.05) by $0.13. The company had revenue of $0.91 million for the quarter, compared to analysts' expectations of $0.82 million. Delcath Systems had a negative trailing twelve-month return on equity of 1,396.28% and a negative net margin of 757.05%. During the same period last year, the firm posted ($0.94) EPS. When did Delcath Systems' stock split? Delcath Systems's stock reverse split on the morning of Tuesday, October 22nd 2019. The 1-100 reverse split was announced on Friday, October 18th 2019. The number of shares owned by shareholders was adjusted after the closing bell on Monday, October 21st 2019. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split. What is Delcath Systems' stock symbol? Delcath Systems trades on the NASDAQ under the ticker symbol "DCTH." How do I buy shares of Delcath Systems? Shares of DCTH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Delcath Systems' stock price today? One share of DCTH stock can currently be purchased for approximately $3.75. How much money does Delcath Systems make? Delcath Systems (NASDAQ:DCTH) has a market capitalization of $37.69 million and generates $3.56 million in revenue each year. The company earns $-25,650,000.00 in net income (profit) each year or ($3.79) on an earnings per share basis. How can I contact Delcath Systems? Delcath Systems' mailing address is 1633 BROADWAY SUITE 22C, NEW YORK NY, 10019. The official website for the company is delcath.com. The company can be reached via phone at 212-489-2100, via email at investorrelations@delcath.com, or via fax at 212-489-2102. This page (NASDAQ:DCTH) was last updated on 1/29/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.